Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 20/20 | 0.60 |
| ▸ | CHEK1 | O14757 | 19/20 | 0.60 |
| ▸ | KIT | P10721 | 6/20 | 0.59 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.55 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.55 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.55 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30086202 | 1.00 | FLT3 (0.60) | FLT3CHEK1KITMAP3K7RPS6KB1 | |
| SCHEMBL26098324 | 0.89 | FLT3 (0.63) | FLT3CHEK1KITMAP3K7RPS6KB1 | |
| SCHEMBL30741460 | 0.88 | FLT3 (0.75) | FLT3CHEK1KITMAP3K7RPS6KB1 | |
| SCHEMBL17545090 | 0.88 | FLT3 (0.75) | FLT3CHEK1KITMAP3K7RPS6KB1 | |
| SCHEMBL30088400 | 0.86 | CHEK1 (0.57) | FLT3CHEK1KITMAP3K7RPS6KB1 | |
| SCHEMBL23754874 | 0.86 | CHEK1 (0.57) | FLT3CHEK1KITMAP3K7RPS6KB1 | |
| SCHEMBL23764827 | 0.85 | CHEK1 (0.75) | FLT3CHEK1KITMAP3K7RPS6KB1 | |
| SCHEMBL30741470 | 0.85 | CHEK1 (0.75) | FLT3CHEK1KITMAP3K7RPS6KB1 | |
| SCHEMBL30468418 | 0.83 | CHEK1 (0.55) | FLT3CHEK1KITMAP3K7RPS6KB1 | |
| SCHEMBL29051888 | 0.83 | CHEK1 (0.55) | FLT3CHEK1KITMAP3K7RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135635-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | Sanford Burnham Prebys Medical Discovery Institute | 2023-05-04 | — | — | US | disclosed |
| US-20230135635-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | Sanford Burnham Prebys Medical Discovery Institute | 2023-05-04 | — | — | US | disclosed |
| CN-115515589-A | ULK1/2 inhibitors and methods of use thereof | 萨克生物研究学院 | 2022-12-23 | — | — | CN | disclosed |
| EP-4103182-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | Salk Institute for Biological Studies (US) | 2022-12-21 | — | — | EP | disclosed |
| WO-2021163629-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2021-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135635-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | ULK2, ULK1, ULK3 | FLT3 1706/4885CHEK1 53/4885KIT 2550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.